Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 216 - 216
Published: Feb. 7, 2025
Cancer
is
one
of
the
leading
causes
morbidity
and
mortality
globally,
responsible
for
approximately
10
million
deaths
in
2022
an
estimated
21
new
cases
2024.
Traditional
cancer
treatments
such
as
surgery,
radiation
therapy,
chemotherapy
often
present
limitations
efficacy
side
effects.
However,
immunotherapeutic
vaccines
have
emerged
a
promising
approach,
leveraging
body’s
immune
system
to
target
eliminate
cells.
This
review
examines
evolving
landscape
vaccines,
differentiating
between
preventive
therapeutic
strategies
highlighting
significance
tumor-specific
antigens,
including
tumor-associated
antigens
(TAAs)
neoantigens.
Recent
advancements
vaccine
technology,
particularly
through
nanotechnology,
resulted
development
nanovaccines,
which
enhance
antigen
stability,
optimize
delivery
cells,
promote
robust
responses.
Notably,
clinical
data
indicate
that
patients
receiving
checkpoint
inhibitors
can
achieve
overall
survival
rates
34.8
months
compared
just
15.7
traditional
therapies.
Despite
these
advancements,
challenges
remain,
immunosuppressive
tumor
microenvironment
heterogeneity.
Emerging
evidence
suggests
combining
nanovaccines
with
immunomodulators
may
by
overcoming
obstacles.
Continued
research
interdisciplinary
collaboration
will
be
essential
fully
exploit
promise
ultimately
more
effective
accessible
patients.
The
future
immunotherapy
appears
increasingly
hopeful
innovative
pave
way
enhanced
patient
outcomes
improved
quality
life
oncology.
Cells,
Journal Year:
2023,
Volume and Issue:
12(17), P. 2159 - 2159
Published: Aug. 28, 2023
In
recent
years,
there
has
been
a
surge
of
interest
in
tumor
microenvironment-associated
cancer
vaccine
therapies.
These
innovative
treatments
aim
to
activate
and
enhance
the
body’s
natural
immune
response
against
cells
by
utilizing
specific
antigens
present
microenvironment.
The
goal
is
achieve
complete
clinical
response,
where
all
measurable
are
either
eliminated
or
greatly
reduced
size.
With
their
potential
revolutionize
treatment,
these
therapies
represent
promising
avenue
for
researchers
clinicians
alike.
Despite
over
100
years
research,
success
therapeutic
vaccines
variable,
particularly
advanced
patients,
with
various
limitations,
including
heterogeneity
microenvironment,
presence
immunosuppressive
cells,
escape
mechanisms.
Additionally,
effectiveness
may
be
limited
variability
patient’s
system
difficulty
identifying
appropriate
each
patient.
challenges,
microenvironment-targeted
have
shown
results
preclinical
studies
become
valuable
addition
current
treatment
“curative”
options.
While
chemotherapeutic
monoclonal
antibody
remain
popular,
ongoing
research
needed
optimize
design
delivery
identify
biomarkers
that
can
predict
guide
patient
selection.
This
comprehensive
review
explores
mechanisms
vaccines,
methods,
role
adjuvants
improving
outcomes.
It
also
discusses
historical
background
examines
state
major
vaccination
immunotherapies.
Furthermore,
limitations
type
analyzed,
providing
insights
into
future
development.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Jan. 9, 2024
Abstract
The
CRISPR
system
is
a
revolutionary
genome
editing
tool
that
has
the
potential
to
revolutionize
field
of
cancer
research
and
therapy.
ability
precisely
target
edit
specific
genetic
mutations
drive
growth
spread
tumors
opened
up
new
possibilities
for
development
more
effective
personalized
treatments.
In
this
review,
we
will
discuss
different
CRISPR-based
strategies
have
been
proposed
therapy,
including
inactivating
genes
tumor
growth,
enhancing
immune
response
cells,
repairing
cause
cancer,
delivering
cancer-killing
molecules
directly
cells.
We
also
summarize
current
state
preclinical
studies
clinical
trials
highlighting
most
promising
results
challenges
still
need
be
overcome.
Safety
delivery
are
important
therapy
become
viable
option.
limitations
overcome,
such
as
off-target
effects,
safety,
site.
Finally,
provide
an
overview
opportunities
in
future
directions
development.
change
landscape
research,
review
aims
overcome
realize
potential.
Vaccines,
Journal Year:
2024,
Volume and Issue:
12(2), P. 134 - 134
Published: Jan. 28, 2024
With
the
rapidly
increasing
demand
for
poultry
products
and
current
challenges
facing
industry,
application
of
biotechnology
to
enhance
production
has
gained
growing
significance.
Biotechnology
encompasses
all
forms
technology
that
can
be
harnessed
improve
health
efficiency.
Notably,
biotechnology-based
approaches
have
fueled
rapid
advances
in
biological
research,
including
(a)
genetic
manipulation
breeding
growth
egg
traits
disease
resistance,
(b)
identification
infectious
agents
using
DNA-based
approaches,
(c)
inclusion
natural
synthetic
feed
additives
diets
their
nutritional
value
maximize
utilization
by
birds,
(d)
such
as
vaccines
various
types
immunostimulants
increase
defensive
activity
immune
system
against
pathogenic
infection.
Indeed,
managing
both
existing
newly
emerging
diseases
presents
a
challenge
production.
However,
recent
strides
vaccine
are
demonstrating
significant
promise
prevention
control.
This
review
focuses
on
evolving
applications
aimed
at
enhancing
immunogenicity,
efficacy,
stability,
delivery.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Aug. 21, 2024
Circular
RNAs
(circRNAs)
are
unique
noncoding
that
have
a
closed
and
stable
loop
structure
generated
through
backsplicing.
Due
to
their
conservation,
stability
tissue
specificity,
circRNAs
can
potentially
be
used
as
diagnostic
indicators
therapeutic
targets
for
certain
tumors.
Many
studies
shown
act
microRNA
(miRNA)
sponges,
engage
in
interactions
with
proteins
translation
templates
regulate
gene
expression
signal
transduction,
thereby
participating
the
occurrence
development
of
variety
malignant
Immunotherapy
has
revolutionized
treatment
cancer.
Early
researches
indicated
involved
regulating
tumor
immune
microenvironment
antitumor
immunity.
CircRNAs
may
potential
important
increasing
sensitivity
immunotherapy
expanding
population
patients
who
benefit
from
cancer
immunotherapy.
However,
few
investigated
correlation
between
In
this
review,
we
summarize
current
on
regulation
different
mechanisms
value
efficacy
goal
providing
new
Journal of Translational Medicine,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Jan. 6, 2025
Immuno-oncology
has
witnessed
remarkable
advancements
in
the
past
decade,
revolutionizing
landscape
of
cancer
therapeutics
an
encouraging
manner.
Among
diverse
immunotherapy
strategies,
mRNA
vaccines
have
ushered
a
new
era
for
therapeutic
management
malignant
diseases,
primarily
due
to
their
impressive
impact
on
COVID-19
pandemic.
In
this
comprehensive
review,
we
offer
systematic
overview
vaccines,
focusing
optimization
structural
design,
crucial
role
delivery
materials,
and
administration
route.
Additionally,
summarize
preclinical
studies
clinical
trials
provide
valuable
insights
into
current
status
treatment.
Furthermore,
delve
discussion
significant
challenges
facing
development
tumor
vaccines.
These
encompass
both
intrinsic
external
factors
that
are
closely
intertwined
with
successful
application
innovative
approach.
To
pave
way
more
promising
future
treatments,
deeper
understanding
immunological
mechanisms,
increasing
number
high-quality
trials,
well-established
manufacturing
platform
crucial.
Collaborative
efforts
between
scientists,
clinicians,
industry
engineers
essential
achieving
these
goals.
Molecular Therapy — Methods & Clinical Development,
Journal Year:
2025,
Volume and Issue:
33(1), P. 101428 - 101428
Published: Feb. 5, 2025
Immunotherapy
is
facing
a
revolution
with
the
advent
of
immune
cell
engineering.
Chimeric
antigen
receptor
(CAR)-T
therapy
has
shown
unprecedented
efficacy
in
B
malignancies
and
now
being
evaluated
other
disease
areas.
Viral
transduction
most
common
method
for
genetic
engineering,
but
presents
important
limitations,
such
as
high
reagent
costs
regulatory
concerns
due
to
mutagenesis
risk.
One
prevailing
non-viral
gene
delivery
strategy
relies
on
electroporation
non-integrating
RNA.
However,
modern
technologies
also
require
rely
use
proprietary
software
transfection
buffers.
Nanoparticle-sensitized
optoporation
represents
an
alternative
transient
permeabilization
cells.
Here,
we
introduce
magnetic
bead-sensitized
optoporation,
which
commercially
available
superparamagnetic
beads
coupled
anti-human
CD3
CD28
antibodies
are
used
photosensitizers
efficient
cargo
into
human
primary
T
cells
We
show
that
generates
functional
mRNA-based
CAR-T
without
affecting
product
memory
phenotype
or
activation
potential.
Importantly,
optoporated
exhibited
greater
proliferation
capacity
relative
electroporated
In
conclusion,
our
findings
suggest
holds
promise
mRNA
therapy.
Frontiers in Bioengineering and Biotechnology,
Journal Year:
2025,
Volume and Issue:
13
Published: March 12, 2025
The
advent
of
mRNA
vaccines,
accelerated
by
the
global
response
to
COVID-19
pandemic,
marks
a
transformative
shift
in
vaccine
technology.
In
this
article,
we
discuss
development,
current
applications,
and
prospects
vaccines
for
both
prevention
treatment
infectious
diseases
oncology.
By
leveraging
capacity
encode
antigens
within
host
cells
directly,
provide
versatile
scalable
platform
suitable
addressing
broad
spectrum
pathogens
tumor-specific
antigens.
We
highlight
recent
advancements
design,
innovative
delivery
mechanisms,
ongoing
clinical
trials,
with
particular
emphasis
on
their
efficacy
combating
diseases,
such
as
COVID-19,
Zika,
influenza,
well
emerging
potential
cancer
immunotherapy.
also
address
critical
challenges,
including
stability,
optimization
immune
responses,
broader
issue
accessibility.
Finally,
review
strategies
advancing
next-generation
aim
overcoming
limitations
technology
enhancing
preventive
therapeutic
approaches
oncological
diseases.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Sept. 5, 2023
New
York-esophageal
cancer
1
(NY-ESO-1)
belongs
to
the
testis
antigen
(CTA)
family,
and
has
been
identified
as
one
of
most
immunogenic
tumor-associated
antigens
(TAAs)
among
family
members.
Given
its
ability
trigger
spontaneous
humoral
cellular
immune
response
restricted
expression,
NY-ESO-1
emerged
promising
targets
for
immunotherapy.
Cancer
vaccines,
an
important
element
immunotherapy,
function
by
presenting
exogenous
source
TAA
proteins,
peptides,
antigenic
epitopes
CD4
